Investor Relations
Key Figures
| IFRS (in EURm except otherwise stated) | 2017 | 2016 |
| Revenues | 2,971.4 | 2,536.6 |
| Adjusted EBITDA | 556.7 | 479.6 |
| Reported EBITDA | 513.2 | 461.1 |
| Basic EPS (EUR) | 12.68 | 10.88 |
| Net Operating Cash Flow | 405.1 | 371.8 |
Outstanding shares:
17,670,244 (at 31.03.2018)
Dividend
The AGM of 20 April 2017 approved the payment of a dividend of EUR 2.00 per share for the year 2016 compared to EUR 1.45 for the previous year.
Financial News
- 12.04.2018Eurofins strengthens its footprint in France with the acquisition of Protec Group’s food and water testing activities
- 04.04.2018Eurofins expands its offering in radioactivity and environmental testing for the nuclear industry with the acquisition of Eichrom Laboratoires in France
- 03.04.2018Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea
- 06.03.2018Eurofins exceeds its recently-upgraded 2017 objectives on a strong growth momentum and raises its objectives for 2018
- 26.02.2018Eurofins further expands its specialty clinical diagnostics footprint with the acquisition of NMDL-LCPL in the Netherlands
Annual Reports
Next Publication: Q1 2018 Interim Management Statement, 24 April 2018 (TBC)
Order a hard copy of the 2017 Annual Report
Eurofins' 20-year IPO value creation study by Marten & Co.
Research Paper by Prof. Brooks
OBSAAR prospectus in French only
